Li-Yu Chen, Shiang-ling Lin, Ya-Yao Huang, Ya-Ting Huang
Published by the 2023 Annual Conference of SNM, Taiwan
Background
18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES
PET/CT) is a new convenient way to screen and analyze metastatic breast cancer (MBC) patients with
uncertain estrogen receptor (ER), which the heterogeneity expression has long been a problem in figuring out how to treat MBC. This systematic review aimed to integrate the study of ER heterogeneity detection by 18F-FES PET/CT.
Methods
PubMed/MEDLINE and Cochrane Library databases were used to perform a comprehensive and systematic search and were updated till August 15, 2022. Two authors independently reviewed the titles and abstracts of the retrieved articles by using the search algorithm and selected the articles based on the inclusion and exclusion criteria. All statistical analyses were conducted using R statistical software.
Results
This systematic review included six studies with 881 breast cancer patients in the
qualitative and quantitative synthesis, which estimated the FES-positive detection rate and the rate of ER
heterogeneity. In included 6 studies, the overall pooled detection rate of 18F-FES PET/CT was 0.82 (95%
CI 0.70–0.89). In addition, the FES uptake threshold of 1.5–1.82 could not only identify the positive ER
but also detect 11.1%–45% ER heterogeneity.
Conclusions
18F-FES PET/CT could identify patients with ER heterogeneity. Future, the study can explore the correlation between ER heterogeneity and prognosis.